Methods
Paired CSF-plasma samples from HBs-antigen-positive patients included in a protocol evaluating HIV neurological complications were analyzed for the detection of HBV-DNA (Cobas Amplicor). The correlations between HBV-DNA in CSF, HIV markers, CSF characteristics, treatment with 3TC and neurological involvement were investigated.
Summary of results
We evaluated 23 HIV-infected adolescents, mean age 17.1 ± 1.8 years, 12 boys, 22 with parenterally acquired HIVinfection. Median CD4 count was 220 lf/mmc (range 1-738). Out of 16 patients with positive plasma HBV-DNA, nine had positive CSF HBV-DNA. We found a positive correlation between HBV-DNA and HIV-RNA in plasma (r = 0.6, p < 0.001) and in CSF (r = 0.5, p = 0.05). HBs antigen was present in the CSF of all nine tested samples. Patients were divided into three groups according to the presence of HBV: nine with both CSF and plasma positive viral load (VL), seven with only plasma-positive HBV and seven without detectable plasma or CSF-DNA. Among the first group, CSF HBV-DNA values were lower compared to the plasma levels (4.11 ± 1.1 vs 7.1 ± 1.4 log10 IU/ml, p = 0.001). In patients ever exposed to 3TC (with a median time of exposure of 26.5 months), we found significantly lower HBV-DNA values in plasma (p < 0.04) and in CSF (p = 0.02) as compared with those never exposed to 3TC. The diversity of neurological diseases made any clinical correlation difficult, although demielinating lesions were found in 7/9 patients with CSF-positive HBV-DNA.
Conclusion
We report for the first time the presence of HBV-DNA in CSF of HIV co-infected patients. HBV was detected in the CSF of more than half of the patients with positive plasma HBV-DNA. CSF HBV-DNA levels were positively correlated with plasma DNA. The clinical significance of the presence of HBV in CSF is a very interesting aspect to be investigated in the future.
